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Abstract: Aim: The present large-series retrospective sought to assess DWBS findings 6‒12 weeks after RIAT in DTC 
patients in various risk groups. In addition, the study compared patients’ simultaneous sTg levels. 
Material and Methods: The follow-up data of 2879 patients who had received RIAT for DTC between 1998 and 2016 
were evaluated for inclusion in the study. The study retrospectively evaluated the following: age at the time of diagnosis; 
gender; histopathological features of thyroidectomy materials (histological subtype, variant, dimension, multi-focality, 
thyroid capsule, and vascular invasion of tumors); TNM stage; ATA classification; sTg, suppressed-serum Tg, and antiTg 
antibody levels; and DWBS findings. Patients were categorized according to sTg level (undetectable, 1‒10 ng/ml, and 
>10 ng/ml). Then, the DWBS findings were analyzed according to sTg level. 
Results: The study analyzed 2184 patients (1805 F, 379 M; mean age: 43.54±12.64). In 2077 (95%) patients, the 
DWBSs performed 6‒12 months after RIAT had shown no pathological uptake throughout the entire body. Pathological 
uptake had been detected in the neck and outside the neck in 88 (4%) and 19 (1%) patients, respectively. All patients 
who had had normal DWBSs also had had undetectable simultaneous sTg levels. In addition, the DWBSs had been 
normal in 187 (8%) patients who had had simultaneous sTg levels> 1 ng/ml and in 286 (13%) patients who had had 
levels > 10 ng/ml. In all patients who had pathological uptake in DWBSs, simultaneous sTg levels were > 1ng/ml, and in 
47, they were> 10 ng/ml.  
Conclusion: Routine DWBS seems to be unnecessary, even in high-risk DTCs. However, in patients who have 
detectable levels of serum sTg, it could be performed to localize the disease and plan patient management.  
Keywords: Differentiated thyroid carcinoma, Diagnostic radioiodine whole-body scintigraphy, Serum thyroglobulin 
measurement.  
INTRODUCTION 
Differentiated thyroid carcinoma (DTC), which 
compromises papillary and follicular cancers, is one of 
the most common malignancies [1-3]. Traditionally, if it 
is indicated, radioiodine ablation treatment (RIAT) has 
been given following total or near-total thyroidectomy. 
Because DTCs have excellent survival rates, routine 
lifetime follow-up is needed [4-6]. Generally, follow-up 
includes periodic measurement of serum thyroglobulin 
(Tg), anti-thyroglobulin antibody (antiTg), and thyroid 
stimulating hormone (TSH)-stimulated serum 
thyroglobulin (sTg) along with simultaneous diagnostic 
radioiodine whole-body scintigraphy (DWBS) from6‒12 
weeks after RIAT.  
Currently, guidelines of the American Thyroid 
Association (ATA) and the European Thyroid 
Association (ETA) do not recommend follow-up with 
DWBSs for low-risk patients [4, 7]. For intermediate- 
and high-risk patients, the role of routine DWBS is 
controversial [8]. There are claims that measuring sTg 
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is more sensitive than DWBS and that DWBS might be 
combined with neck ultrasound (US) to check the 
success of RIAT. However, the additional information 
that DWBS can provide could help to localize recurrent 
or persistent disease and to evaluate the possibility of 
additional radioiodine treatments.  
The present large-series retrospective sought to 
assess DWBS findings 6‒12 weeks after RIAT in DTC 
patients in various risk groups. In addition, the study 
compared patients’ simultaneous sTg levels. 
MATERIALS AND METHODS 
Patients 
The follow-up data of 2879 patients who had 
received RIAT for DTC between 1998 and 2016 were 
evaluated for inclusion in the study. The study excluded 
patients who had undergone subtotal thyroidectomy, 
had not had a detailed histopathological examination of 
thyroidectomy material, had received RIAT within the 
previous 2 years, or had been lost to follow-up. 
Therefore, the study included 2184 patients in the 
analysis. All 2184had received RIAT following total or 
near-total thyroidectomy ± central ± lateral-compart- 
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ment lymph-node dissection. In all patients, after 6‒12 
months of RIAT, a DWBS with 185 MBq of Iodine-131 
(I-131) had been performed. In all patients, neck US 
and suppressed-serum Tg measurements had been 
evaluated yearly. In cases of clinical suspicion of 
recurrence, computed tomography (CT) of the thorax, 
18F-Flourodeoxyglucose (FDG) positron emission 
tomography (PET)/CT, and additional DWBSs had 
been performed. In cases of documented persistent or 
recurrent disease, patients had undergone additional 
surgeries and additional radioiodine treatments.  
Data and Statistical Analysis 
The study retrospectively evaluated the following: 
age at the time of diagnosis; gender; histopathological 
features of thyroidectomy materials (histological 
subtype, variant, dimension, multi-focality, thyroid 
capsule, and vascular invasion of tumors); TNM stage; 
ATA classification; sTg, suppressed-serum Tg, and 
antiTg antibody levels; and DWBS findings. Patients 
were categorized according to sTg level (undetectable, 
1‒10 ng/ml, and >10 ng/ml). Then, the DWBS findings 
were analyzed according to sTg level. Continuous data 
are expressed as the mean and standard deviation or 
as the median and interquartile range. Categorical data 
are presented as numbers of patients and percentages. 
Compatibility of the DWBS findings with the sTg levels 
was analyzed using the Chi-square test. SPSS 
software (version 20.0; SPSS Inc.; Chicago, IL, USA) 
was used for statistical analysis.  
RESULTS 
Patients 
The study analyzed 2184 patients (1805F, 379M; 
mean age: 43.54±12.64). Table 1 shows the patients’ 
descriptive data. All patients had received RIAT at 
doses of from 30‒150 mCi, according to the risk group 
they were in. In the post-ablative DWBSs obtained 5‒8 
days after RIAT, accumulation of radioactivity had been 
detected in the neck and outside the neck in 2061 
(94%) and 83 (4%) patients, respectively. In 40 (2%) 
patients, the post-ablative DWBSs had been normal. 
Mean pre-ablative TSH sTg levels were calculated as 
28.1±49.4 (min‒max: 0.22‒300) ng/ml. 
In 2077 (95%) patients, the DWBSs performed 6‒12 
months after RIAT had shown no pathological uptake 
throughout the entire body. Pathological uptake had 
been detected in the neck and outside the neck in 88 
(4%) and 19 (1%) patients, respectively. All patients 
who had had normal DWBSs also had had 
undetectable simultaneous sTg levels. In addition, the 
DWBSs had been normal in 187 (8%) patients who had 
had simultaneous sTg levels> 1 ng/ml and in 286 
(13%) patients who had had levels > 10 ng/ml. In all 
patients who had pathological uptake in DWBSs, 
simultaneous sTg levels were > 1ng/ml, and in 47, they 
were> 10 ng/ml.  
Table 1: Patients’ Demographic and Follow-Up Data 
Parameter 
Age  
F 1805 (83%) 
M 379 (17%) 
Subtype 
Papillary 1969 (90%) 
Follicular 134(6%) 
Mixed 32(1%) 
Well-differentiated carcinoma with unknown malign 
potential  49(3%) 
Multi-centricity 
Positive 1415 (65%) 
Negative 769 (35%) 
Thyroiditis 
Positive 611 (28%) 
Negative 1573 (72%) 
Thyroid capsule invasion 
Positive 749 (34%) 
Negative 1435 (66%) 
Vascular invasion 
Positive 169 (8%) 
Negative 2015 (92%) 
TNM stage 
1 1779 (81%) 
2 153 (7%) 
3 165 (8%) 
4 87 (4%) 
ATA classification 
Low-risk 1604 (73%) 
Intermediate-risk 477 (22%) 
High-risk 103 (5%) 
ETA classification 
Very low 433 (20%) 
Low 1324 (60%) 
High 427 (20%) 
(ATA: American Thyroid Association; ETA: European Thyroid Association) 
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Table 2 summarizes additional data on the 
comparison of DWBS findings and simultaneous serum 
sTg levels based on ATA risk groups. One examples 
for positive and negative DWBS were shown in  
Figure 1.  
DISCUSSION 
DWBS is recommended as a simple, cost-effective, 
highly accurate method of following up DTC patients 
after RIAT [9]. It is recommended to be 
performedusing74‒185 MBq of I-131 and endogenous 
or exogenous TSH stimulation in combination with 
simultaneous serum sTg measurements. However, 
because serum Tg measurement kits are highly 
sensitive, sensitivity and the role of routine DWBS are 
controversial. Because of radiation dosimetry and 
potential side effects, the role of DWBS should be 
redefined in managing DTCs.  
Table 2: Comparison of DWBS Findings and Simultaneous Serum sTg Levels Based on ATA Risk Classifications 
  Simultaneous Serum sTg Levels 
ATA Risk Group DWBS <1 ng/ml 1‒10 ng/ml >10 ng/ml 
Normal 1417 116 27 
Uptake in the neck 0 34 9 Low 
Uptake outside the neck 0 1 0 
Normal 344 64 35 
Uptake in the neck 0 20 14 Intermediate  
Uptake outside the neck 0 0 0 
Normal 30 7 37 
Uptake in the neck 0 3 8 High 
Uptake outside the neck 0 2 16 
(ATA: American Thyroid Association; Tg: Thyroglobulin;ng/ml: nanogram per milliliter; DWBS: diagnostic whole-body scintigraphy). 
 
Figure 1: Examples for patients with elevated serum Tg level and positive and negative DWBS. 
4    International Journal of Nuclear Medicine Research, 2017, Vol. 4, No. 1 Soydal et al. 
ATA guidelines do not recommend routine DWBS in 
low-risk patients. In intermediate- and high-risk 
patients, the role of DWBS is unclear. It may be of 
value in following up these groups. However, it is only 
an expert opinion, and application time is not stated 
[10]. Furthermore, the literature includes limited studies 
in this area [8, 11-13]. Meer et al. evaluated DWBS 
findings and simultaneous serum sTg levels in 112 
high-risk patients [8], concluding that DWBSs offered 
no information in addition to that provided by the sTg 
levels. Similarly, Verburg et al. concluded that routine 
DWBS could be omitted in high-risk patients in their  
44-patient group [11]. In the present retrospective 
study, 103 patients were in the high-risk group, and the 
results were similar to those of other studies: the 
present study found no differences in the sensitivity of 
DWBSs between high- and low-risk groups. However, 
Robbins et al. advocated performing routine DWBS in 
all DTCs, claiming that serum Tg measurements alone 
could not detect all the metastases that could be 
detected by DWBSs [13]. The present study analyzed 
the DWBS findings and simultaneous serum sTg levels 
in a large patient group, finding no additional 
recurrence or persistent disease that could be seen on 
DWBSs but not detected by serum sTg measurements. 
Undetectable serum Tg levels have high negative-
predictive value in the absence of serum antiTg 
antibodies. However, in the case of the presence of 
circulating antiTg antibodies, DWBSs could become 
more important [14]. In patients with no detectable 
antiTg antibodies, it is quite rare to detect disease 
recurrence by a DWBS without accompanying serum 
sTg levels. In such cases, false-positive reasons that 
could trap I-131should be considered [9]. 
To our knowledge, the present retrospective study 
is the largest in the literature comparing serum sTg 
measurements and DWBSs. The present study found 
that a routine DWBS after 6‒12 months of RIAT did not 
detect any recurrent of persistent disease in addition to 
that detected by serum sTg measurements, even in 
intermediate- and high-risk patients. Therefore, sTg 
seems more sensitive to persistent or recurrent 
disease. The amount of residual or recurrent disease 
and its I-131 avidity are very important to detectability 
by DWBSs. However, when a DWBS is positive, it can 
localize the disease and can give information about its 
radioiodine avidity, which is an important prognostic 
factor (15). For these reasons, DWBSs could be 
performed for patients who have detectable levels of 
serum sTg. 
CONCLUSIONS 
Routine DWBS seems to be unnecessary, even in 
high-risk DTCs. However, in patients who have 
detectable levels of serum sTg, it could be performed 
to localize the disease and plan patient management.  
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